2011-01-19

International Society for Cellular Therapy (ISCT) Launches Inaugural Cell Therapy Commercial Development Focus Group on Peripheral Vascular Disease


Vancouver (ots/PRNewswire) - In keeping with itscommitment to connect industry, regulatory experts, therapeuticsocieties and translational centers to advance emerging cellulartherapies, ISCT announces its first commercial development focusgroup addressing Cell Therapies for Peripheral Vascular Disease(PVD).

PVD is a condition in which the arteries that carry blood to thearms or legs become narrowed or clogged. In a primary care populationdefined by age and common risk factors the prevalence of PVD isapproximately one in three(1). Critical Limb Ischemia (CLI) is a verysevere condition of PVD with patients suffering severe pain and skinulcers which can lead to limb amputation. CLI has a 15-30% mortalityrate at 5 years.(2)

To address this debilitating condition ISCT has created aprogressive forum to unite an expert panel and facilitate in depth,open discussion of whether, and how, cell therapy can meet the unmetneeds of these patients. The focus group will take place in New York,USA January 21 2011 in partnership with the Cardiovascular ResearchFoundation (http://www.crf.org), sponsor of the Sixth InternationalConference on Cell Therapy for Cardiovascular Disease.

"As we enter the era of 300+ patient Phase 3 studies, it iscrucial for the research community to identify appropriate end pointsthat correlate with meaningful clinical outcomes," said WarrenSherman, MD, Director, Regenerative Cardiovascular Research at TheJack H. Skirball Center for Cardiovascular Research. "From there,trial design can be optimized to assess clinical efficacy and,hopefully, improve outcomes of patients with CLI. These patients havea very poor prognosis. To help them with cell-based therapy would bea huge advance, and would have implications for patients withvascular disease of other organ systems."

Ed Horwitz, M.D. PhD, President of ISCT strongly agreed, "thelaunch of this series of focus groups is the latest initiativethrough which ISCT is building alignment with academia and industryto expedite the development and maturation of the field andultimately bring cell therapy treatments to patients faster. It isISCT's intent that the international field of cell therapy andregenerative medicine will be able to benefit from the focus groupsthrough public open access to the final report and outcomes aspublished in per reviewed journals."

Visit http://www.celltherapyfocusgroups.com for furtherinformation on the agenda and registration details.

The ISCT focus group initiative follows the successful launch ofISCT's Industry Community in August 2010. See: ISCT - Media.(http://www.celltherapysociety.org/index.php/about-us/media)

ISCT welcomes the following new corporate members into theIndustry Community for 2011:

Patrons: Aastrom Biosciences Inc., BD Biosciences Inc. BioLifeSolutions Inc., Pfizer Regenerative Medicine, Pluristem TherapueticsInc. Partners; CaridianBCT Inc., Sartorius Stedim Biotech GmbH.,STEMCELL Technologies Inc. Supporters: CellGenix GmbH., PharmacellB.V. Members: Apceth GmbH & Co. Preservation Solutions Inc, BeikeBiotechnology Co.Ltd., DCi Biotech Inc., Tengion Inc., STEMSOFTSoftware Inc., ZMKS International Cancer Therapy Biotechnology Co.Ltd.

The complete list of members can be viewed on the IndustryCommunity page of http://www.celltherapysociety.org

ISCT is a global association driving the translation ofscientific research to deliver innovative cellular therapies topatients. Established in 1992, its membership and leadershipcomprises world-class scientists, clinicians, technologists,biotech/pharma and regulatory professionals from around the worldfocused on pre-clinical and translational aspects of developing celltherapy products.

References

1. Hirsch AT et al. JAMA. 2001;286:1317-1324

2. Hirsch AT et al. Circulation. 2006;113:e463-654

For further information: Robert Deans Chair, ISCT Commercialization Committee Senior VP of Regenerative Medicine Athersys, Inc +1-216-526-2433 cell rdeans@athersys.com Jane Arthurs ISCT Executive Director +1-604-630-5495 Jane@celltherapysociety.org

ots Originaltext: International Society for Cellular TherapyIm Internet recherchierbar: http://www.presseportal.de

Contact:CONTACT: For further information: Robert Deans, Chair, ISCTCommercialization Committee, Senior VP of Regenerative Medicine, Athersys,Inc, +1-216-526-2433 cell, rdeans@athersys.com; Jane Arthurs, ISCTExecutive Director, +1-604-630-5495, Jane@celltherapysociety.org

International Society for Cellular Therapy

Zurück zur Übersiche Medizin-Nachrichten

Preisvergleich Medikamente
Medikament oder PZN:   
In Zusammenarbeit mit Medizinfuchs

News

International Society for Cellular Therapy (ISCT) Launches Inaugural Cell Therapy Commercial Development Focus Group on Peripheral Vascular Disease

Medizin-News